Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Therapy Name NVP-TNKS656 + Trametinib
Synonyms
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
NVP-TNKS656 NVP656 Tankyrase Inhibitor 10 NVP-TNKS656 is a small molecule that inhibits Tankyrase, resulting in decreased Beta-catenin signaling, and potentially leading to reduced tumor growth (PMID: 26224873, PMID: 30944457, PMID: 31897238).
Trametinib Mekinist GSK1120212 MEK inhibitor (Pan) 22 MEK1 Inhibitor 20 MEK2 Inhibitor 18 Mekinist (trametinib) inhibits MEK 1 and 2, which potentially leads to reduced tumor cell proliferation (PMID: 27956260). Mekinist (trametinib) is FDA approved for melanoma patients harboring BRAF V600E or BRAF V600K mutations, and in combination with Tafinlar (dabrafinib) for BRAF V600E/K-mutant melanoma, BRAF V600E- mutant non-small cell lung cancer, and BRAF V600E-mutant anaplastic thyroid cancer (FDA.gov).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CTNNB1 S33Y PIK3CA mut colon cancer resistant NVP-TNKS656 + Trametinib Preclinical - Cell culture Actionable In a preclinical study, PIK3CA mutant colon cancer cells expressing CTNNB1 S33Y demonstrated suppression of cell death following Mekinist (trametinib) and NVP-TNKS656 combination treatment in culture (PMID: 30944457). 30944457
PIK3CA mutant colon cancer predicted - sensitive NVP-TNKS656 + Trametinib Preclinical - Cell line xenograft Actionable In a preclinical study, Mekinist (trametinib) treatment in combination with NVP-TNKS656 enhanced cell death in PIK3CA mutant colon cancer cells in culture, and induced apoptosis and inhibited tumor growth in a cell line xenograft model (PMID: 30944457). 30944457
CTNNB1 mut PIK3CA mut colon cancer predicted - resistant NVP-TNKS656 + Trametinib Preclinical - Cell culture Actionable In a preclinical study, Mekinist (trametinib) treatment in combination with NVP-TNKS656 did not induce cell death in PIK3CA and CTNNB1 mutant colon cancer cells in culture (PMID: 30944457). 30944457
CTNNB1 wild-type PIK3CA mut colon cancer predicted - sensitive NVP-TNKS656 + Trametinib Preclinical - Cell culture Actionable In a preclinical study, Mekinist (trametinib) treatment in combination with NVP-TNKS656 induced cell death in colon cancer cells with wild-type CTNNB1 and mutant PIK3CA in culture (PMID: 30944457). 30944457

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status


Additional content available in CKB BOOST